NAB2–STAT6 fusions have been shown to function as transcriptional activators and upregulate the expression of cancer-promoting EGR1 target genes including FGFR1 and NTRK1, as well as IGF genes in SFT patient samples [4,5]. The gene discussed is STAT6; the disease is cancer.